Need Help? Chat Online or Toll Free: 1-800-891-0844
Cart (0)

Hyrimoz (Adalimumab)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Sign Up

Prescription Required

  • Related Products & Conditions

  • Product Details

    Description

    Hyrimoz (adalimumab-adaz) is a biosimilar to Humira (adalimumab), a tumor necrosis factor (TNF) inhibitor indicated for the treatment of multiple chronic inflammatory conditions. It is approved for use in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. Hyrimoz exerts its therapeutic effect by binding to TNF-a, a pro-inflammatory cytokine, thereby blocking its interaction with TNF receptors and reducing inflammation and tissue destruction associated with autoimmune diseases.

    Directions

    Hyrimoz is administered via subcutaneous injection. Dosing varies depending on the indication, age, and patient-specific factors. For example:

    • Rheumatoid arthritis: 40 mg every other week
    • Crohn’s disease (adult): Initial dose of 160 mg, followed by 80 mg at week 2, then 40 mg every other week
    • Plaque psoriasis: Initial dose of 80 mg, followed by 40 mg every other week starting one week later

    Patients may self-administer Hyrimoz after appropriate training. The prefilled syringe or autoinjector should be stored in a refrigerator and allowed to reach room temperature before use. Injection sites should be rotated to avoid skin irritation.

    Ingredients

    Each 0.8 mL of Hyrimoz contains:

    • Adalimumab-adaz 40 mg
    • Mannitol
    • Glacial acetic acid
    • Sodium acetate
    • Polysorbate 80
    • Water for injection

    The formulation is preservative-free and latex-free.

    Contraindications

    Hyrimoz is contraindicated in patients with:

    • Known hypersensitivity to adalimumab or any component of the formulation
    • Active tuberculosis or other severe infections such as sepsis and opportunistic infections
    • Moderate to severe heart failure (particularly NYHA class III/IV, in some indications)

    Cautions

    Before initiating therapy, patients should be evaluated for latent or active tuberculosis, and appropriate treatment should be started if needed. During treatment, patients should be monitored for signs of infection, malignancies, demyelinating disorders, and cytopenias. Live vaccines should be avoided during treatment. Use with other biologic immunomodulators (e.g., anakinra or abatacept) is not recommended due to increased risk of infection. Periodic monitoring of complete blood count, liver enzymes, and hepatitis B virus status is recommended.

    Side Effects

    Common side effects of Hyrimoz include:

    • Injection site reactions (pain, erythema, pruritus)
    • Upper respiratory infections
    • Headache
    • Rash
    • Nausea
    • Sinusitis

    Serious adverse effects may include:

    • Serious infections (e.g., tuberculosis, fungal, bacterial)
    • Malignancies (e.g., lymphoma, skin cancer)
    • Hepatitis B reactivation
    • Demyelinating disease
    • Heart failure exacerbation
    • Lupus-like syndrome

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14374

  • Product Reviews